Mr. Elliot McKerr reports

HYTN ANNOUNCES RESULTS OF 2024 ANNUAL GENERAL AND SPECIAL MEETING

HYTN Innovations Inc. has released the results of its annual general and special meeting of shareholders held on May 23, 2024 (the AGSM).

Shareholders voted in favour of all the matters submitted before the AGSM, as set out in the company's notice of meeting and information circular dated April 18, 2024, including:

• Setting the size of the board to three directors;
• Re-electing Elliot McKerr, Jason Broome and Eli Dusenbury as directors until the next annual meeting of shareholders of the company;
• Reappointing Crowe MacKay LLP as the company's auditor for the ensuing year;
• Approving the company's omnibus equity incentive plan, as more particularly described in the circular.

"We appreciate the support we have received from shareholders at this year's AGSM, and we are looking forward to the upcoming year as we continue to pursue our ambitious goals," states Mr. McKerr, chief executive officer.

About HYTN Innovations Inc.

HYTN formulates, manufactures, markets and sells premium products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids. HYTN's mission is to become the top provider of these products in all markets where such products are federally regulated. To achieve this, the company focuses on identifying market opportunities and quickly bringing its innovative products to market through its elevated development platform.

We seek Safe Harbor.